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Summary
Background Psoriasis is an inflammatory long-term condition involving comorbidi-
ties, unhealthy lifestyle and significant life impact. Patients’ understanding of pso-
riasis is limited and support lacking. The Common-Sense Model of Self-
Regulation of Health and Illness emphasizes the role of illness and treatment
beliefs on coping and self-management. New ‘Pso Well’ patient materials
informed by the model, addressed psoriasis as a long-term condition, medication
management and lifestyle behaviours.
Objectives To investigate whether Pso Well materials (i) broaden understanding
of psoriasis without increasing anxiety; (ii) are acceptable; and (iii) comprise fea-
tures that appear to effect change.
Methods The Revised Illness Perceptions Questionnaire (IPQ-R modified) and the
Hospital Anxiety and Depression Scale (HADS) were administered in patients before
and after intervention. Numerical rating scales assessed perceptions of change in
understanding and anxiety resulting from engagement with the materials. Qualita-
tive interviews explored acceptability and perceived ‘active ingredients’.
Results Fifty-five patients completed pre- and postintervention questionnaires
(56% female; median age 59 years). Postintervention, a large effect size was
indicated in two IPQ-R domains – illness coherence [t(55) = 348, P = 0001
(two-tailed), g2 = 019] and personal control [t(55) = 298, P = 0004 (two-
tailed), g2 = 014] – and a medium effect in one, treatment control [t
(55) = 208, P = 0042 (two-tailed), g2 = 008]. HADS scores did not change.
For numerical rating scales, 80% of participants reported increased understand-
ing of psoriasis and none reported increased anxiety. Interviews with 19
patients indicated the materials were acceptable and usable. Factors reported to
broaden understanding and promote engagement with self-management
included linking of related disease aspects, personally relevant content and
high-quality design.
Conclusions High-quality, theory-based psoriasis materials are acceptable to patients
and can improve understanding and sense of control without increasing anxiety.
© 2017 The Authors. British Journal of Dermatology
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What’s already known about this topic?
• Psoriasis is associated with comorbidities, unhealthy lifestyle and significant life
impact.
• Patients’ understanding of psoriasis is limited, self-management support is lacking
and disengagement from healthcare services is common.
What does this study add?
• The new, theory-informed Pso Well patient materials address psoriasis as a long-
term condition; medications management and lifestyle behaviour.
• The Pso Well patient materials can increase understanding of psoriasis, promote
feelings of self-worth and encourage a desire to engage in self-management and
behaviour change, without increasing anxiety or depression.
What are the clinical implications of this work?
• The Pso Well patient materials could support clinical consultations by helping
patients recognize the remitting–relapsing nature of psoriasis.
• This will help to improve understanding of the disease, as well as providing a
clearer rationale for treatment adherence and lifestyle behaviour change.
Psoriasis is a complex, long-term inflammatory skin condition
affecting at least 2% of the U.K. population.1 It is associated
with high levels of physical and psychological disability,2–5
comorbidities6–10 and significant life impact.11,12 While indi-
viduals with psoriasis have additional risk factors for13 and
higher mortality from14 cardiovascular disease, recent evidence
suggests that psoriasis in the absence of inflammatory arthritis
is not an independent risk factor.13
Unhealthy lifestyle behaviours15–20 and obesity21 are more
common in individuals with psoriasis, complicating under-
standing of comorbidities13,18 and contributing to risks of
psoriasis onset and/or exacerbation,16,22–27 although patients
and nonspecialist clinicians may be unaware of these associa-
tions. Improving lifestyles may improve outcomes;27–31 how-
ever, complex interactions between physiological and
behavioural processes can be compounded by high levels of
associated psychological distress. Distress can increase risk
behaviour (e.g. smoking) and reduce motivation and capacity
to engage in healthy behaviours.32
Dissatisfaction with psoriasis management,33,34 problematic
medication adherence35 and disengagement from health ser-
vices are common among patients.34,36 Clinicians express
low confidence in managing psoriasis comorbidities, includ-
ing supporting healthy lifestyle.37–40 Patients’ understanding
of psoriasis is limited,41 and patient information rarely
addresses comorbidity risk or rationale for lifestyle modifica-
tion. There is little evidence to support the effectiveness of
generic education-based interventions in psoriasis for patient
self-management.42,43 While tailored, disease-specific pro-
grammes appear to be more promising,44,45 these interven-
tions may be labour intensive and relatively costly, and do
not explicitly recognize the central importance of patient
understanding in self-management. Informing patients of
additional possible health risks could further increase anxiety.
Lack of ‘illness coherence’, or the mismatch between under-
standing underlying disease mechanisms and corresponding
self-care activities, is a barrier to action, reducing perceived
personal control of psoriasis with consequent suboptimal
outcomes.34
The Common-Sense Model of Self-Regulation of Health
and Illness (CS-SRM)46 provides an explanation as to how an
individual’s beliefs about their condition and its treatment
influence their emotional and behavioural responses,47
including self-care behaviours. The five key beliefs high-
lighted in the model relate to symptoms attributed to the
condition, its cause, chronicity, levels of perceived controlla-
bility or curability, and its perceived consequences.48 In
2002, the concept of ‘illness coherence’ was added to the
CS-SRM to describe an individual’s ability to hold a congru-
ent working model of their symptoms.49 Patients’ beliefs
have been shown to predict health outcomes and are amen-
able to change in a range of long-term conditions including
psoriasis.50 Thus, changing patients’ understanding of psoria-
sis and the relevance of health behaviours may help increase
motivation to engage in appropriate self-management. How-
ever, exposing patients to a revised picture of psoriasis as an
incurable condition associated with comorbidities risks creat-
ing or compounding distress.
Guided by the Medical Research Council framework for
complex healthcare interventions51,52 and evidence from the
Identification and Management of Psoriasis-Associated Co-
morbidiTy (IMPACT) programme,53 we developed and tested
new ‘Pso Well’ patient-focused materials to: (i) improve ill-
ness coherence (i.e. broaden patient understanding of psoriasis
© 2017 The Authors. British Journal of Dermatology
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as a systemic long-term condition without increasing anxiety);
(ii) improve understanding of treatments by linking disease
mechanisms with effective self-care options, including beha-
vioural change; and (iii) identify aspects of the intervention
that patients perceive as motivating them to change (i.e.
mechanisms of action).
Materials and methods
Study design
This was a within-group, before-and-after feasibility and
acceptability study to develop, test and evaluate new patient
materials for psoriasis, described using TIDieR guidance.54
Materials development, design and content
Guiding principles informed the materials’ presentation
and communication style (Table 1).55–58 Materials were
designed iteratively, by mapping key concepts against the
CS-SRM domains (to increase understanding by relating
information to patients’ own personal experience of psori-
asis rather than simply increasing knowledge about the
disease), and refining content and style in consultation
with the IMPACT Patient User Group, specialist clinicians
and graphic designers (Table S1; see Supporting Informa-
tion).
The collaborative design and refinement process resulted in
15 paper-based leaflets (see Figure 1 for design and Table 2
for content).
Materials testing
Sampling and recruitment
A community-based sample of primary-care patients from a
previous study59 was invited to participate (University of
Manchester ethics reference 14269).
Study procedure and outcome measures
Informed written consent was obtained by post. Data collected
at baseline via postal questionnaire prior to intervention
included the following. Firstly, three domains of the Revised
Illness Perceptions Questionnaire (IPQ-R).49 Both the revised
and earlier versions of this instrument have been widely used
in the psoriasis population50,60–67 and have good evidence for
reliability and validity.49 The illness coherence domain score
was the primary outcome. Secondary outcome measures were
the personal control and the treatment control domains. Illness
coherence scores and treatment control scores are each calcu-
lated by summing the scores of five items, each with a possi-
ble score of 1–5 (range 5–25). The personal control score is
similarly calculated; however, this domain contains six items
(range 6–30).
Secondly, two further items, which were administered to
assess other aspects of illness coherence specific to psoriasis.
Data from these items were analysed separately from the origi-
nal IPQ-R illness coherence domain. They were: (i) ‘I have a
clear picture or understanding of other conditions that are
associated with psoriasis (sometimes called comorbidities)’
Table 1 Guiding principles for Pso Well patient materials development
Principles Techniques Aim
Broadening understanding (beliefs)
about psoriasis and treatment
options
Clearly written, accurate information directly
addressing key beliefs in CS-SRM
Use of analogies and metaphors to
communicate complex disease and treatment
mechanisms
Directly addressing common emotional
responses to psoriasis
Improve illness coherence
Improve understanding of relapsing–remitting
nature of psoriasis
Improve understanding of links between
treatment options and underlying disease
processes
Recommendations for writing
effective health communication
Textual and graphical coherence
Attention to readability and usability
Chunking information into ‘bite-size’ sections
Pilot testing with target audience
Promote optimum information processing
Content of personal relevance to
people with psoriasis
Inclusion of issues and experiences grounded in
in-depth qualitative research with patients and
clinicians managing psoriasis
Advice and suggestions from current best
evidence-based self-management approaches
Promote understanding of comorbidities
Provide rationale for personally relevant lifestyle
behaviour change and medication adherence
Positive messages Use of self-affirmation to build confidence and
motivation
Hopeful tone
Modelling functional coping
Counteract possible increase in anxiety resulting
from new understanding of psoriasis as a
lifelong, incurable inflammatory condition
CS-SRM, Common-Sense Model of Self-Regulation of Health and Illness.
© 2017 The Authors. British Journal of Dermatology
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and (ii) ‘Having a healthy lifestyle can improve my psoriasis
or psoriasis flares’.
Thirdly, the Hospital Anxiety and Depression Scale (HADS),
which was used to assess anxiety and depression.68 This is a
widely used tool that has been used extensively in patients
with psoriasis and shown to have good reliability and validity
in these populations.69–71 It comprises seven items assessing
anxiety symptoms and seven assessing depression symptoms.
Anxiety and depression scores are produced by summing the
scores from a four-point Likert scale (0–3) with a maximum
possible value of 21 for each; scores under seven indicate no
or normal levels of anxiety or depression.
Fourthly, the Simplified Psoriasis Index, administered to
assess current psoriasis severity, historical course of the condi-
tion and perceived psychological and social impact.72 Baseline
Simplified Psoriasis Index scores were used to characterize the
sample of participants.
Participants were given 2 weeks to read and reflect upon
the materials and were invited to identify information that
was new or made them think differently about psoriasis or its
management. Views were recorded on a ‘relevance’ chart
according to two categories: ‘highly relevant now’ and ‘rele-
vant in the past’. Once completed and returned, postinterven-
tion assessments were collected by post. These included the
three domains of the IPQ-R as above; the two additional ill-
ness coherence questions; HADS; and two simple numerical
rating scales (NRS) to enable participants to indicate changes
(positive, negative or none) in (i) understanding and (ii) anx-
iety, which the participants attributed as resulting directly
from interacting with the materials. Figure 2 shows the study
process flowchart.
Process evaluation
A subset of participants purposively sampled for age, sex, pso-
riasis severity and responses to the outcome measures was
invited to participate in follow-up interviews based on a flexi-
ble topic guide (Table S2; see Supporting Information). This
was to evaluate the usability and acceptability of the materials
and to identify any perceived influences on understanding
psoriasis (i.e. ‘active ingredients’).
Data analyses
Paired-sample t-tests assessed change in illness perceptions and
anxiety and depression scores before and after intervention.
All quantitative analyses used SPSS version 22 (IBM, Armonk,
NY, U.S.A.).
Qualitative data collection and analysis were carried out
concurrently.73 Data were managed in NVivo 10 (QSR Inter-
national, Doncaster, Australia) and explored iteratively for
similarities and differences within and across interviews using
principles of framework analysis.74 Data were labelled in a ser-
ies of coding steps. The first author (P.A.N.) led and
Fig 1. Pso Well patient materials design.
Table 2 Content of Pso Well patient materials
Leaflet set Leaflet title Content
Introductory (two leaflets) Psoriasis: new for you Signposting for patients with a new diagnosis of
psoriasis
Knowing your psoriasis Signposting for patients with a long-standing diagnosis
of psoriasis
Understanding psoriasis as a
complex long-term
condition (three leaflets)
Changing phases What is psoriasis?
Linking mind and body Associated comorbidities
Your journey with psoriasis Cardiovascular risk and mood factors
Medications management (six
leaflets)
Treatment overview Explanation of first-, second- and third-line treatments
for psoriasis and relevance for stages of diseaseTopical treatments
Emollients
Steroid-based topicals
Light therapy
Systemics and biologics Practical tips for treatment use. Reflective activities to
enhance adherence
Lifestyle management (four
leaflets)
Why does my weight matter? Weight/nutrition
Keeping active feeling good Physical activity
Smokeless Smoking
Is your glass half full? Alcohol
© 2017 The Authors. British Journal of Dermatology
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coordinated the coding process to generate a draft conceptual
framework (key themes). A series of analysis meetings
between authors P.A.N., K.K. and L.C. took place regularly
during coding. Data were considered from the perspectives of
dermatology, health psychology and health service research, to
identify whether and how exposure to the materials had
prompted any change in participants’ understanding or coher-
ence in relation to psoriasis. The second author (K.K.) applied
the draft conceptual framework to a subset of data, and the
final list of key themes was agreed. Data collection was con-
cluded when key themes were fully developed.73
Results
Participants
Of the 127 invited, 58 participants completed the ‘relevance’
chart and 55 completed the pre- and postintervention ques-
tionnaires. Of the 24 invited for interview, 19 accepted. The
sampling frame for the interviews was the total number of
participants (n = 55) who completed the postintervention
assessments. Individuals were selected based on maximizing
heterogeneity on the following four attributes: age, sex, psori-
asis severity and responses to the item, ‘Since reading the leaf-
lets, my understanding of psoriasis has changed’.
In order to obtain meaningful feedback on the materials
from the interviews we purposively sampled people who
reported their understanding of psoriasis to have changed a
lot after reading the leaflets (e.g. participant 3, female, aged
42 years and participant 5, male, aged 69 years) and those
who reported no change in understanding (e.g. participant 6,
male, aged 44 years and participant 12, female, aged
67 years). The ranges of scores recorded for individuals in the
interview sample on other variables reflected those of the lar-
ger sample used in the quantitative analysis. The qualitative
subsample also included those with both positive views (e.g.
participant 1, female, aged 65 years and participant 2, male,
aged 62 years) and negative views (e.g. participant 9, female,
aged 59 years and participant 11, female, aged 59 years)
about the relevance of the content of the patient support
materials.
Figure 3 shows the final study sample (with dropouts at
each stage) and Table 3 presents the sample demographics for
the quantitative (outcome measures) and qualitative (process
evaluation) data.
Quantitative study (outcome measures)
Revised Illness Perceptions Questionnaire
Postintervention, a statistically significant difference between
the means was found in the primary outcome ‘illness coher-
ence’ [from 160 to 175; t(55) = 348, P = 0001 (two-
tailed)], indicating a large effect size (g2 = 019). Notably,
both the personal control and treatment control domains also
improved postintervention, with a large [t(55) = 298,
P = 0004 (two-tailed), g2 = 014] and moderate [t
(55) = 208, P = 0042 (two-tailed), g2 = 008] effect size,
respectively (Table 4). Data for all domains are reported in
Table S3 (see Supporting Information).
The materials resulted in changes in understanding of speci-
fic aspects of psoriasis: 31 of 54 (57%) participants reported
not having a clear understanding of comorbidities preinterven-
tion, reducing to 19 (35%) postintervention; and 31 of 53
(58%) of the sample did not know about the relevance of life-
style behaviours preintervention, reducing to 19 (36%)
postintervention (the similarity in reported frequencies is
coincidental).
Hospital Anxiety and Depression Scale
There were no clinically or statistically significant increases in
HADS anxiety or depression scores after exposure to the mate-
rials, implying that improvements in understanding of the nat-
ure of psoriasis occurred without a corresponding increase in
either anxiety or depression (Table 4). Cronbach’s a scores
for the IPQ-R and the HADS domains range from 091 to
072, indicating high levels of internal reliability for these
scores (Table 4).
Numerical rating scale scores
Overall 80% of participants reported that their understanding
of psoriasis increased postintervention; none reported that
their anxiety increased after reading the leaflets and 16%
reported reduced anxiety (Table 5).
Pre-testing 
IPQ-R, HADS and 
SPI questionnaires 
posted, completed 
and returned 
preintervention 
Intervention
Pso Well® materials 
and response 
recording charts 
posted to 
participants   
Post-testing 
IPQ-R, HADS and 
NRS scales completed 
and returned 
postintervention 
Process evaluation 
In-depth qualitative 
interviews 
2 weeks 
Fig 2. Pso Well patient materials study
process flowchart. IPQ-R, Revised Illness
Perceptions Questionnaire; HADS, Hospital
Anxiety and Depression Scale; SPI, Simplified
Psoriasis Index; NRS, numerical rating scale.
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Leaflet relevance
The majority of participants indicated that the content of the
leaflets was highly relevant. Notably, many indicated that it
would have had relevance earlier in the course of their disease
(Table 6).
Process evaluation (qualitative study)
Analysis generated three themes explaining participants’ per-
spectives on the Pso Well materials and what influenced their
understanding of psoriasis: (i) ‘Seeing the bigger picture: pso-
riasis as more than a skin condition’; (ii) ‘Personalizing
Participants invited
n = 127
Preintervention assessment (baseline)
completed
n = 84
Exposure to patient materials
(intervention)
n = 84
Postintervention assessment completed
n = 55
Participated in in-depth interview
n = 19
‘Relevance’ chart completed
n = 58
31 did not reply
12 withdrew –
5 were too busy
3 had mild psoriasis (thought research
not relevant to them)
2 were ill
2 no reason given
12 did not reply
3 returned comments but did not complete
‘relevance’ chart
11 withdrew –
3 had mild psoriasis (thought research
not relevant to them)
2 were ill
2 were too busy
2 found instructions confusing
2 no reason given
Invited for in-depth interview
n = 24 2 did not reply
3 were too busy
Fig 3. Final study sample with dropouts.
Table 3 Sample characteristics
Characteristics
Participants: quantitative
outcomes study
Participants: qualitative process
evaluation study
Female, n (%) 55 (56) 19 (63)
Current age (years), median (range) 59 (31–79) 59 (31–69)
Age at diagnosis (years), median (range) 29 (7–65) 40 (7–62)
Years with psoriasis, median (range) 28 (2–67) 19 (3–49)
Psoriasis severity (SPI severity subscale) 48 mild, 5 moderate, 2 severe 16 mild, 1 moderate, 2 severe
SPI, Simplified Psoriasis Index.
© 2017 The Authors. British Journal of Dermatology
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psoriasis: developing illness coherence’ and (iii) ‘Managing
psoriasis differently: making changes’. All themes and sub-
themes are presented alongside illustrative data extracts
(Table 7).
Theme 1: seeing the bigger picture: psoriasis as more
than a skin condition
Newly discovered aspects of psoriasis Discovering hitherto unknown
or unexplained aspects of psoriasis through exposure to the
materials was a commonly reported experience. The leaflets
enabled participants to build up a wider picture of psoriasis as
a complex long-term condition affecting more than the skin.
Many were unaware of comorbidities, links with lifestyle
behaviours, treatments available and the need for treatment
review. Some learned about the mechanisms involved in psori-
asis for the first time, for example the relapsing–remitting nat-
ure, its systemic basis, the plaque formation process and
inflammatory links.
Enablers of learning Features enabling participants to assimilate
information, link aspects of psoriasis together and gain a sense
of reassurance rather than distress included plain-language
style, colour coding to aid navigation, ‘chunking’ of informa-
tion and the positive tone of language used.
Unintended consequences of exposure to Pso Well materials There were
some unintended consequences of exposure to the new mate-
rials, highlighting that acquiring new information about psori-
asis was not always a positive or even neutral process.
Some participants expressed disappointment in health ser-
vices for failing to provide similar information; others blamed
themselves for not actively seeking information. Participants
expressed regret about not having access to the materials ear-
lier in life, believing that this could have improved how they
managed psoriasis.
Almost every participant interviewed learned something
new from the materials, enabling them to link disease aspects
together in a new way. Learning that psoriasis was a complex
long-term condition appeared to be offset by the positive,
hopeful tone of the materials, but some disappointment was
expressed that information had not been made available ear-
lier.
Theme 2: personalizing psoriasis – developing illness
coherence
Making personal sense of psoriasis Participants reported that the
materials helped ‘make sense’ of psoriasis. Sense making
involved finding a ‘reference point’, linking disease aspects to
self, understanding how psoriasis affects individuals personally
and ways to manage it. A new awareness of the bidirectional
links between psoriasis, mood and lifestyle behaviours and
where these were personally relevant became apparent for
some.
Enablers of engagement with the materials Several factors enabled par-
ticipants to engage with the materials. These included person-
ally relevant or resonant content that confirmed or validated
previously unarticulated feelings and thoughts (particularly
Table 5 Self-reported changes in understanding and anxiety after
reading Pso Well materials
Increased,
n (%)
Neutral,
n (%)
Decreased,
n (%)
Understanding 44 (80) 11 (20) 0
Anxiety 0 46 (84) 9 (16)
Table 4 Revised Illness Perceptions Questionnaire (IPQ-R) domain
and Hospital Anxiety and Depression Scale (HADS) changes pre- and
postintervention
IPQ-R domain Cronbach a
Mean
changea g2
Effect
size P-value
Illness
coherence
(primary
target)
091 149 019 Large ≤ 0001
Personal
control
091 142 014 Large ≤ 001
Treatment
control
072 079 008 Medium ≤ 005
HADS Cronbach a
Mean
changea SD t P-value
Anxiety 088 025 234 076 045
Depression 084 026 263 073 047
aPre- vs. postintervention.
Table 6 Number and percentage of participants reporting on leaflet
‘relevance’ (n = 58)
Leaflet
Highly
relevant now
Relevant in
the past
Changing phases 29 (50) 29 (50)
Linking mind and body 26 (45) 35 (60)
Your journey with psoriasis 38 (67) 42 (72)
Treatment overview 26 (45) 32 (55)
Topical treatments 32 (55) 29 (50)
Emollients 33 (57) 30 (52)
Steroid-based topicals 24 (41) 33 (57)
Light therapy 12 (21) 21 (36)
Systemics and biologics 14 (24) 29 (50)
Why does my weight matter? 31 (53) 37 (64)
Keeping active feeling good 34 (58) 32 (55)
Smokeless 7 (12) 25 (43)
Is your glass half full? 19 (33) 27 (47)
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Table 7 Themes and subthemes
Theme 1: Seeing the bigger picture: psoriasis as more than a skin condition
Sub-theme Data extract
Newly discovered aspects of psoriasis
Learning about co-morbidities It was something I didn’t know. . .I thought that perhaps [psoriatic
arthritis] applied to me. . .I didn’t realise that psoriasis and arthritis
could be combined (P1 female 65)
Learning about lifestyle behaviour links A lot of the information was new to me. . .[leaflets] gave me a lot to
think about. . .I didn’t realise smoking and alcohol could affect
[psoriasis] (P3 female 42)
Learning about treatments I didn’t even know there were things for psoriasis other than the
ointment I’m using – I thought everybody used that! I wasn’t aware
there were other types of treatment. . .light therapy and that (P5
male 69)
Learning about disease/treatment mechanisms Nobody had ever explained why you get. . .plaques. . .it’s your skin
cells speeded up and you’ve got a build-up of what you can
physically see (P17 female 32)
Enablers of learning
Plain language style The [materials] were at the right level without patronising people –
it was just at the right level for me and just going in (P4 female 57)
Ease of navigation [Leaflets] were uniform, so they’d all look nice and you’d choose
your colour. . .and could go straight to it (P9 female 59)
Chunking of information It’s little bits at a time, little bits of information. . .bite-sized, that’s it
(P7 female 45)
Positive/hopeful tone It just puts the two things together [psoriasis and heart health]. The
way it’s written isn’t threatening at all, it just makes it plain that
there could be a link (P2 male 62)
Unintended consequences
Disappointment in health services It was a bit disappointing really that my doctor had never said there are new things (P5 male 69)
Self-blaming Having the leaflets, it made me angry with myself for not looking things up. . .I was a bit angry
with myself and annoyed (P8 female 31)
Regret that information not made
available earlier
When I saw all of [materials] I thought – all right, so this is the kind of
information you can get access to! If we had this back then it would’ve
been brilliant. . .I wouldn’t have felt so alone with [psoriasis] (P6 male 44)
Theme 2: Personalising psoriasis: developing illness coherence
Sub-theme Data extract
Making personal sense of psoriasis
Finding a ‘reference point’ I had no reference points or anything to know what should be
happening or how bad [psoriasis] could get, so by having the
leaflets – they said – if this doesn’t work you can try this (P8
female 31)
Linking disease aspects to self I recognised the sort of things that were me. . .a greater knowledge
from reading all the different things and relating certain aspects to
myself. . .I do understand [psoriasis] more now than I did (P4
female 57)
New awareness of bi-directional links I hadn’t put the links together in my mind. I realised being
withdrawn had made my psoriasis worse but hadn’t. . .linked that
one relates to the other. By having the leaflets I was able to
understand all the little things that can affect it, things I hadn’t
thought about (P8 female 31)
Enablers of engagement with materials
Personally relevant/resonant content
(acknowledging emotional impact)
I thought. . .yes that’s how it is. . .there it is on the page. . .it’s not just
a skin condition, it’s the whole range of emotions that come with it
as well (P6 male 44)
Perceived trustworthiness of the materials The source of the information is the thing. You get all sorts of stuff
on the internet, put up by all sorts of people, bloggers of every
description. . .if you can go to a trusted source. . .the NHS is very
much in that category (P18 male 61)
Perceived ‘high quality’ of materials content and design [Leaflets] were quite professional. . .and. . .attractive, like you want
to read them – they’re not just your boring leaflets in waiting rooms
in the NHS. . .you want to pick them up (P17 female 32)
(continued)
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Table 7 (continued)
Theme 2: Personalising psoriasis: developing illness coherence
Sub-theme Data extract
Changing emotions and cognitions (feelings and thoughts)
Reduced feelings of self-blame/increased confidence It’s not my fault is one of the biggest things. By knowing all these
things affect [psoriasis], it’s not something I’ve done. . .that’s made
this happen. . .by having the leaflets. . . I felt more confident to go
and sit and have breakfast in a coffee shop (P8 female 31)
Increased feelings of self-esteem (being valued) To be given something like [materials]. . .made me as a psoriasis
sufferer feel valued, because so often dermatology – psoriasis – is
the bottom of the pile. . .so this. . .the way it was presented. . .actually
made me feel for once, somebody was trying to make me feel
valued about it (P19 female 67)
Bringing previously ‘unconscious’ thoughts to the fore I kind of made a personal link and I thought – hey – when I get
stressed there are times when my psoriasis starts getting worse.
So maybe I’d better watch that. Maybe I can do something about it
(P17 female 32)
Self-questioning about managing psoriasis differently When I saw the leaflets. . .it did make me question things more,
especially the use of lotions and things, that made me re-think my
journey with my doctor over the years, how I’ve let things lapse and
not ask for further consultations. Those leaflets made me
think, well actually, I should be more proactive (P3 female 42)
Theme 3: Managing psoriasis differently: making changes?
Sub-theme Data extract
Materials as ‘stand-alone’ tool
Consulting in a different way
Using medications differently
That leaflet was good in that it made me go back and think about
[medication] and I got on a different topical lotion – changed it for
the first time in as long as I can remember (P3 female 42)
I make sure I look after [skin] properly and put the creams on the
right way. . .I take more care. . .it’s reading [materials] and trying to
do things differently than I was before. . .sometimes I used
to just ignore [psoriasis] (P1 female 65)
Taking action to address lifestyle behaviour It [re-joining Weight Watchers] was after that [reading
leaflets]. . .because I felt better. Somebody understood me,
understood my condition, understood how I feel (P7 female 45)
Perceived change mechanisms
Tracking psoriasis with body diagram Looking at [body diagram] from 5 months ago I’d have said
[psoriasis] didn’t do that [fluctuate]. I’m shocked looking now. . .
when I completed the leaflets I felt I was in a good place, but my
psoriasis is much better months along the line than it was (P3 female 42)
Identifying concerns and priorities with activities/charts Seeing it written down made me realise that there were phases [to
psoriasis] because – yes it’s controlled. . .but. . .something would
trigger it off again. It. . .made me realise what was bothering me (P4
female 57)
Identifying goals and strategies with activities/charts You need a strategy. . .you need a plan. . .and I started to. . .write
down what I need to do and then – right. . .the next stage is this (P1
female 65)
Increasing intention/motivation to make
changes through engagement with activities
The activities was something I was able to use to help me. . .being
able to put that tick. . .gave you a boost – like – yeah, you’re doing
what you need to do, you’re going to get there (P8 female 31)
Materials as a ‘shared’ management tool
Materials as a useful to ‘share’ with doctor It would open up a conversation, if [GP] was to say – we’ve
got these leaflets – where are you? It might make you feel. . .there’s
somebody caring and trying to improve the situation (P5 male 69)
‘Shared’ tool as an incentive to change The doctor could actually use [leaflet] and say – look – what we’re
going to do is I need you to keep a diary, to keep noting and. . .I
want you to fill this in. Then the person is going to use the leaflet
rather than. . .stick it in my drawer when I get home (P17 female 32)
Materials as a support for clinicians’ practice I imagine [materials] would help GPs massively because I wonder
how much GPs actually update their information about [skin]
conditions. . .invaluable information here that you could use with the
doctor (P3 female 42)
(continued)
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having the emotional impact of psoriasis acknowledged), the
perceived trustworthiness of the materials, and their high-
quality content and design.
Changes to emotions and cognitions (feelings and thoughts) Participants
reported that engagement with the materials promoted an
improved personalized understanding of psoriasis (illness
coherence). This encouraged an increased sense of personal
control and/or prompted new ways of thinking about self-
management. Participants stated they: (i) felt less inclined to
self-blame for having psoriasis; (ii) experienced increased self-
confidence and self-esteem (as a result of ‘warranting’ high-
quality, attractive health-focused materials); (iii) became
aware of new concepts (e.g. psoriasis and links with mood;
the concept of ‘goal-setting’); and (iv) began to self-question
about how to manage psoriasis differently (e.g. medication
use, consulting behaviour and lifestyle behaviours).
Participants identified factors that promoted engagement
with the materials: the trusted source and high quality, con-
veying a message that people with psoriasis were valued.
Theme 3: managing psoriasis differently: making changes?
Differing reasons were given for the materials’ potential to
influence behavioural change. Some participants used them
immediately as a ‘stand-alone’ self-management tool; some
viewed them as a ‘shared’ management tool for use in con-
junction with a health professional; and, more rarely, some
participants were resistant to using the materials at all.
Pso Well materials as a ‘stand-alone’ self-management tool Some partic-
ipants (who generally perceived their psoriasis as bothersome)
used the materials as a ‘stand-alone’ tool to change psoriasis
management. Behavioural changes reported were: consulting
differently, seeking referral to secondary care, using medica-
tions as recommended, taking steps to address low mood, and
acting to make lifestyle behavioural changes. Thus, some par-
ticipants were able to use the materials of their own volition
without support from a third party.
Perceived mechanisms promoting intention or motivation for change Partici-
pants who had been able to use the materials to make changes
identified the ‘activity’ sections as useful facilitators of change.
The activities (charts and exercises) enabled participants to
track flares and identify concerns, priorities and goals, and to
find strategies to achieve goals and increase intention to make
changes.
Pso Well materials as a ‘shared’ management tool Some also viewed
the materials as a beneficial self-management tool, for use in
partnership with health professionals such as general practi-
tioners or specialist clinicians. This was particularly, but not
exclusively, where individuals valued further explanation of
the rationale for change (e.g. the mechanisms and evidence to
support lifestyle behaviour links) or individualized support to
identify goals and plans. The materials were viewed as useful
for prompting meaningful discussions between patients and
professionals, facilitating ‘shared’ monitoring and increasing
the incentive for medication adherence and lifestyle changes.
Participants believed that using the materials together with a
clinician could enhance their credibility further, encouraging
sustained patient engagement. The materials were also viewed
as useful support for professionals in clinical practice.
Resistance to using the materials as a self-management tool There were
some reports of resistance to using the materials, from partici-
pants who saw no need to change their self-care routine if pso-
riasis was well controlled or mild. However, particularly in
relation to lifestyle behaviour change, others appeared to react
to an initial perception of the ‘top-line’ messages, which could
be experienced as threatening (similarly to commonly heard
‘fear-based’ or rule-bound health messages). If participants
were already feeling negative about lifestyle changes, initial
reading appeared to compound this response, acting as a barrier
to further reading or deeper engagement with the materials.
In summary, the Pso Well materials were used indepen-
dently by some participants as tools for self-management,
while others saw benefit in sharing them to monitor and man-
age psoriasis in partnership with a clinician. Others had
Table 7 (continued)
Theme 3: Managing psoriasis differently: making changes?
Sub-theme Data extract
Resistance to using the materials
Psoriasis experienced as mild/not bothersome I don’t think I was so keen on the [activities]. . .because it’s saying
how much is [psoriasis] affecting you at the moment and it wasn’t
affecting me. . .my psoriasis isn’t normally that bad (P9 female 59)
Feeling ‘bombarded’ with lifestyle behaviour
change messages in general
I’m not sure anything in the [weight] leaflet would help. . .it’s on the
telly all the time, there’s stop smoking things all over. . .all these
years I’ve been trying to lose weight by doing what the doctors and
everyone have said. . .and I think I was probably feeling like
strangling them. (P9 female 59)
Perceiving messages as rigid/rule-based For me personally it smacks a bit of work. . .you went on
various courses and it would be ‘let’s have a target here’ and. . .
‘we need to write an action plan!’. . .oh crikey here we go again (P13 female 64)
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difficulty conceiving of their use, particularly in relation to
lifestyle behaviour change, and appeared ‘defensive’ and
unwilling to receive such health messages in general.
Discussion
The findings from the Pso Well patient materials study indi-
cate that carefully designed, high-quality, theory-based
resources are acceptable to patients with psoriasis and can
improve their understanding, coherence and sense of control,
without a corresponding increase in anxiety. Furthermore, the
materials appeared to have effects on beliefs about psoriasis, as
well as emotional responses, of some participants, increasing
their motivation or intention to change self-management
behaviour.
This study is the first to develop, test and evaluate an inter-
vention for psoriasis that targets patients’ understanding of dis-
ease and treatment. This was a gap identified from a previous
IMPACT programme of work,34,37–39 and represents a new way
of thinking about health communication in the psoriasis field.
The authors recognized the possibility that a new or deeper
understanding of the lifelong, relapsing–remitting nature of the
condition might increase distress and that learning of the risks
of comorbidities may be potentially anxiety provoking. In fact,
understanding, motivation and intention all increased with no
corresponding change in anxiety or depression. Several features
of the Pso Well materials appeared to facilitate this.
Firstly, the high-quality, accurate content directly targeted
illness beliefs, for example linking disease mechanisms with
treatment options including the relevance of behaviour change
for self-management and helping patients recognize the remit-
ting–relapsing nature of psoriasis. Notably, materials to
improve understanding of disease also appeared to provide
patients with a clearer rationale for treatments and vice versa.
Secondly, design values such as attention to readability and
usability appeared to aid information processing. Writing for a
basic reading ability while avoiding oversimplification, which
may deter those with greater literacy levels, is recommended
in health communication but challenging to accomplish.75
The Pso Well leaflets appeared to achieve this balance. Addi-
tionally, their high-quality ‘look and feel’ conveyed that psori-
asis (a condition that often involves appearance-related
concerns) warrants attractive, engaging materials and that their
target audience is valued. This contrasts markedly with the
lack of design values in many health communication resources
identified in our previous work.76
Thirdly, personally resonant and relevant information
addressed emotional effects directly, acknowledging emotional
impact and the rationale for self-management using advice
based on best evidence and improving understanding rather
than simply increasing knowledge as many educational inter-
ventions do.
Finally, the positive, hopeful tone (emphasizing that people
could take steps to help control their psoriasis and minimize
the impact the condition had on their lives, even if comor-
bidities did arise in the future) appeared to reassure and
encourage participants to engage with the materials, offsetting
potentially threatening health messages about psoriasis as a
more complex disease. The associated unintended conse-
quences of exposure to the materials identified by the process
evaluation highlight that information-giving is not a neutral
process and that attention to tone, language and message
framing are crucial components in health communication.
This apparently simple intervention took the form of high-
quality paper leaflets; however, the content had undergone
extensive development and testing. Participants’ accounts sug-
gest that our use of written communication, including phras-
ing, use of metaphor and context, was important for
clarifying or reinforcing messages that may have been superfi-
cially familiar but not previously understood in ways that
could be of use in planning self-care. Additionally, the study
suggests that changing understanding may be a precursor to
behaviour change. A trial of a face-to-face intervention to
modify patients’ illness and treatment beliefs based on the
same theoretical model as this study resulted in behavioural
changes (increases in walking) that were maintained for at
least 2 years.77 It is promising that a lower-cost intervention
may have at least some of the same outcomes.
The positive results must be interpreted with some caution
due to the lack of a separate control group; however, restricting
participants’ exposure to the intervention to a 2-week period
makes it unlikely that any confounding factor promoted the
change in understanding within the time frame. Precise mea-
sures of responsiveness for the IPQ-R domains and HADS are
not readily available for this population, and this is a potential
limitation of using these measures to assess the effects of expo-
sure to these materials. We also recognize that this self-selected
sample may not be representative of the wider psoriasis popula-
tion in that they may be more ‘engaged’ with health messages.
However, the strong study design, which, following the Medi-
cal Research Council guidelines,52 measured the effects of the
intervention and evaluated the intervention process to identify
perceived mechanisms of action, can usefully inform future
research. Patients in this study perceived that the materials could
be a useful tool for ‘shared’ management of psoriasis in partner-
ship with clinicians. A parallel skills-based Pso Well interven-
tion demonstrated positive effects on clinicians’ knowledge and
skills in managing psoriasis.78 It is possible that there would be
additional synergistic effects of these materials if used by
patients in collaboration with healthcare professionals who have
undertaken the training.
In conclusion, the new Pso Well materials are acceptable
to patients and can improve understanding, coherence and
sense of control in relation to psoriasis, without a correspond-
ing increase in anxiety.
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